Gene Editing is the ability to make highly specific changes in the DNA sequence of a living organism, essentially customizing its genetic makeup. It demonstrates great potential in gene research, gene therapy and genetic improvement. The Gene Editing concept includes major US-listed companies whose businesses are involved in gene editing.
- 1389.037
- -24.179-1.71%
Cantor Analysts Call for RFK Jr. Replacement Following Ousting of Marks at FDA
S&P 500 Exits Q1 in the Red - Here Are Its Largest Losers and Winners
BlueBird Shares Are Up Today: What's Going On?
Vertex Discontinues Development Of Type 1 Diabetes Candidate After Disappointing Data
12 Health Care Stocks Moving In Monday's Intraday Session
How Peter Marks' FDA Departure Is Impacting Pharma, Biotech Stocks
Vertex Non-opioid Painkiller Journavx Gets Mixed ICER Review
Gene Therapy-Focused Bluebird Bio Receives Rival Takeover Offer, Stock Jumps
Barclays Maintains Overweight on Bluebird Bio, Lowers Price Target to $8
Bluebird Bio Analyst Ratings
Vertex Pharmaceuticals Analyst Ratings
Eli Lilly's Lepodisiran Slashes Inherited Heart Disease Risk Factor by 94% in Phase 2 Trial
Key Deals This Week: XAI Acquires X; Bluebird Bio, Nvidia, Dollar Tree and More
Trump's Medical Tariffs Could Significantly Hurt These European Healthcare Firms
Vertex to Take $400M Impairment Charge as It Abandons Diabetes Drug Program
12 Health Care Stocks Moving In Friday's After-Market Session
'Bluebird Gets New M&A Bid, Seeking To Top Private Equity Offer' - Endpoints News
Beam Upgraded to Buy at BofA Securities on Recent Genetic Condition Treatment
This Applied Materials Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday
Netflix, Vertex Pharmaceuticals And More On CNBC's 'Final Trades'